N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA

Mol Cancer. 2004 Jan 16:3:3. doi: 10.1186/1476-4598-3-3.

Abstract

Background: Cellular senescence is a state in which mammalian cells enter into an irreversible growth arrest and altered biological functions. The senescence response in mammalian cells can be elicited by DNA-damaging agents. In the present study we report that the DNA-damaging agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) is able to induce senescence in the HCT-116 colon cancer cell line.

Results: Cells treated with lower concentrations of MNNG (0-25 microM) for 50 h showed a dose-dependent increase in G2/M phase arrest and apoptosis; however, cells treated with higher concentrations of MNNG (50-100 microM) showed a senescence-like G0/G1 phase arrest which was confirmed by increased expression of beta-galactosidase, a senescence induced marker. The G2/M phase arrest and apoptosis were found to be associated with increased levels of p53 protein, but the senescence-like G0/G1 phase arrest was dissociated with p53 protein levels, since the p53 protein levels decreased in senescence-like arrested cells. We further, determined whether the decreased level of p53 was a transcriptional or a translational phenomenon. The results revealed that the decreased level of p53 protein in senescence-like arrested cells was a transcriptional phenomenon since p53 mRNA levels simultaneously decreased after treatment with higher concentrations of MNNG. We also examined the effect of MNNG treatment on other cell cycle-related proteins such as p21, p27, cyclin B1, Cdc2, c-Myc and max. The expression levels of these proteins were increased in cells treated with lower concentrations of MNNG, which supported the G2/M phase arrest. However, cells treated with higher concentrations of MNNG showed decreased levels of these proteins, and hence, may not play a role in cell cycle arrest. We then examined a possible association of the expression of APC protein and telomeric DNA signals with cellular senescence in MNNG-treated cells. We found that protein and mRNA levels of APC were drastically reduced in cells treated with higher concentrations of MNNG. The loss of APC expression might lead to chromosomal instability as well as microtubular disorganization through its dissociation with tubulin. In fact, the protein level of alpha-tubulin was also drastically decreased in senescence-like arrested cells treated with higher concentrations of MNNG. The levels of telomeric DNA also decreased in cells treated with higher concentrations of MNNG.

Conclusions: These results suggest that in response to DNA alkylation damage the senescence-like arrest of HCT-116 cells was associated with decreased levels of APC protein, microtubular organization, and telomeric DNA.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenomatous Polyposis Coli Protein / metabolism*
  • Aging / drug effects*
  • Apoptosis / drug effects
  • CDC2 Protein Kinase / metabolism
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cyclin B / metabolism
  • Cyclin B1
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / metabolism
  • DNA, Neoplasm / metabolism*
  • Dose-Response Relationship, Drug
  • G1 Phase / drug effects
  • G2 Phase / drug effects
  • HCT116 Cells / chemistry
  • HCT116 Cells / metabolism*
  • Humans
  • Methylnitronitrosoguanidine / pharmacology*
  • Microtubules / metabolism*
  • Proto-Oncogene Proteins c-myc / metabolism
  • Resting Phase, Cell Cycle / drug effects
  • Telomere / metabolism*
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Adenomatous Polyposis Coli Protein
  • CCNB1 protein, human
  • CDKN1A protein, human
  • Cyclin B
  • Cyclin B1
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • DNA, Neoplasm
  • Proto-Oncogene Proteins c-myc
  • Tumor Suppressor Protein p53
  • Methylnitronitrosoguanidine
  • CDC2 Protein Kinase